scispace - formally typeset
Open AccessJournal ArticleDOI

Beta-Blockers and Outcome in Heart Failure and Atrial Fibrillation: A Meta-Analysis

TLDR
In this article, the effect of beta blockade on outcome in patients with heart failure (HF) and atrial fibrillation (AF) was analyzed. But, the authors did not find a significant interaction of the effects of beta-blocker therapy in AF versus sinus rhythm.
Abstract
Objectives The purpose of this study was to analyze the effect of beta blockade on outcome in patients with heart failure (HF) and atrial fibrillation (AF). Background Beta-blockers are widely used in patients with HF and AF. Recommendation in current HF guidelines, however, is based on populations in which the most patients had sinus rhythm. Whether beta-blockers are as useful in AF is uncertain. Methods Studies were included that investigated the effect of placebo-controlled, randomized beta-blocker therapy in patients with AF at baseline and HF with reduced systolic left ventricular ejection fraction (LVEF) l40%. Results We identified 4 studies, which enrolled 8,680 patients with HF, and 1,677 of them had AF (19%; mean 68 years of age; 30% women); there were 842 patients treated with beta-blocker, and 835 with placebo. In AF patients, beta-blockade did not reduce mortality (odds ratio [OR]: 0.86 [95% confidence interval (CI): 0.66 to 1.13]; p = 0.28), while in sinus rhythm patients, there was a significant reduction (OR: 0.63 [95% CI: 0.54 to 0.73]; p l 0.0001). Interaction analysis showed significant interaction of the effects of beta-blocker therapy in AF versus that in sinus rhythm (p = 0.048). By meta-regression analysis, we did not find confounding by all relevant covariates. Beta-blocker therapy was not associated with a reduction in HF hospitalizations in AF (OR: 1.11 [95% CI: 0.85 to 1.47]; p = 0.44), in contrast to sinus rhythm (OR: 0.58 [95% CI: 0.49 to 0.68]; p l 0.0001). There was a significant interaction of the effects of beta-blocker therapy in AF versus that in sinus rhythm (p l 0.001). Conclusions Our findings suggest that the effect of beta-blockers on outcome in HF patients with reduced systolic LVEF who have AF is less than in those who have sinus rhythm.

read more

Citations
More filters
Journal ArticleDOI

Comorbidity of atrial fibrillation and heart failure

TL;DR: A possible role for AF in its aetiology is suggested, possibly as a trigger for ventricular fibrosis, and restoring sinus rhythm by catheter ablation seems successful in the medium term and improves HF symptoms, functional capacity, and left ventricular function.
Journal ArticleDOI

Rate control in atrial fibrillation

TL;DR: Although rate control is a top priority and one of the first management issues for all patients with atrial fibrillation, many issues remain.
Journal ArticleDOI

Impact of Atrial Fibrillation on Exercise Capacity in Heart Failure with Preserved Ejection Fraction: A RELAX Trial Ancillary Study

TL;DR: The RELAX (Phosphodiesterase-5 inhibition to improve clinical status and exercise capacity in atrial fibrillation) trial as mentioned in this paper was a multicenter randomized trial testing the impact of sildenafil on peak VO2 in stable outpatients with chronic HFpEF.
References
More filters
Journal ArticleDOI

Guidelines for the management of atrial fibrillation The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)

TL;DR: Estimates of expected health outcomes for larger societies are included, where data exist, and the level of evidence and the strength of recommendation of particular treatment options are weighed and graded according to pre-defined scales.
Journal ArticleDOI

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

Åke Hjalmarson, +350 more
- 12 Jun 1999 - 
TL;DR: Metoprolol controlled release/extended release (CR/XL) once daily in addition to standard therapy improved survival and the drug was well tolerated.
Journal ArticleDOI

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial

TL;DR: Beta-blocker therapy had benefits for survival in stable heart-failure patients and should not be extrapolated to patients with severe class IV symptoms and recent instability because safety and efficacy has not been established in these patients.
Journal ArticleDOI

The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure

TL;DR: Carvedilol reduces the risk or death as well as the risk of hospitalization for cardiovascular causes in patients with heart failure who are receiving treatment with digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor.
Related Papers (5)

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

Åke Hjalmarson, +350 more
- 12 Jun 1999 -